Christopher Gibson Recursion Pharmaceuticals, Inc. (RXRX) insider trading activity

Christopher Gibson is Chief Executive Officer of RECURSION PHARMACEUTICALS, INC.. Currently has a direct ownership of 913,839 shares of RXRX, which is worth approximately $3.78 Million. The most recent transaction as insider was on Dec 19, 2025, when has been sold 40,000 shares (Class A Common Stock) at a price of $4.5 per share, resulting in proceeds of $180,000. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 914K

4.23% 3M change

24.06% 12M change

Total Value Held $3.78 Million

Christopher Gibson Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Dec 19 2025	SELL Open market or private sale	$180,000 $4.5 p/Share	40,000 Reduced 4.19%	913,839 Class A Common Stock
Dec 19 2025	BUY Conversion of derivative security	-	40,000 Added 4.02%	953,839 Class A Common Stock
Dec 04 2025	SELL Bona fide gift	-	20,000 Reduced 2.14%	913,839 Class A Common Stock
Dec 04 2025	SELL Open market or private sale	$185,200 $4.63 p/Share	40,000 Reduced 4.11%	933,839 Class A Common Stock
Dec 04 2025	BUY Conversion of derivative security	-	60,000 Added 5.8%	973,839 Class A Common Stock
Nov 19 2025	SELL Open market or private sale	$166,400 $4.16 p/Share	40,000 Reduced 4.19%	913,839 Class A Common Stock
Nov 19 2025	BUY Conversion of derivative security	-	40,000 Added 4.02%	953,839 Class A Common Stock

Nov 17 2025	SELL Payment of exercise price or tax liability	$167,214 $4.14 p/Share	40,390 Reduced 4.23%	913,839 Class A Common Stock
Nov 04 2025	SELL Open market or private sale	$208,400 $5.21 p/Share	40,000 Reduced 3.94%	974,229 Class A Common Stock
Nov 04 2025	SELL Bona fide gift	-	20,000 Reduced 2.05%	954,229 Class A Common Stock
Nov 04 2025	BUY Conversion of derivative security	-	60,000 Added 5.59%	1,014,229 Class A Common Stock
Oct 23 2025	SELL Open market or private sale	$570,000 $5.7 p/Share	100,000 Reduced 9.49%	954,229 Class A Common Stock
Oct 23 2025	BUY Conversion of derivative security	-	100,000 Added 8.66%	1,054,229 Class A Common Stock
Oct 10 2025	SELL Open market or private sale	$604,000 $6.04 p/Share	100,000 Reduced 9.31%	974,229 Class A Common Stock
Oct 10 2025	SELL Bona fide gift	-	20,000 Reduced 2.05%	954,229 Class A Common Stock
Oct 10 2025	BUY Conversion of derivative security	-	120,000 Added 10.05%	1,074,229 Class A Common Stock
Sep 25 2025	SELL Open market or private sale	$476,000 $4.76 p/Share	100,000 Reduced 9.49%	954,229 Class A Common Stock
Sep 25 2025	BUY Conversion of derivative security	-	100,000 Added 8.66%	1,054,229 Class A Common Stock
Sep 10 2025	SELL Open market or private sale	$471,000 $4.71 p/Share	100,000 Reduced 9.31%	974,229 Class A Common Stock
Sep 10 2025	SELL Bona fide gift	-	20,000 Reduced 2.05%	954,229 Class A Common Stock
Sep 10 2025	BUY Conversion of derivative security	-	120,000 Added 10.05%	1,074,229 Class A Common Stock
Aug 26 2025	SELL Open market or private sale	$484,000 $4.84 p/Share	100,000 Reduced 9.49%	954,229 Class A Common Stock
Aug 26 2025	BUY Conversion of derivative security	-	100,000 Added 8.66%	1,054,229 Class A Common Stock
Aug 15 2025	SELL Payment of exercise price or tax liability	$227,799 $5.64 p/Share	40,390 Reduced 4.06%	954,229 Class A Common Stock
Aug 11 2025	SELL Bona fide gift	-	10,000 Reduced 1.0%	994,619 Class A Common Stock

Christopher Gibson

Chief Executive Officer

Salt Lake City, UT

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells RXRX shares.

Notify only if

Value

Insider Trading

Get notified when an Recursion Pharmaceuticals, Inc. insider buys or sells RXRX shares.

Notify only if

Operation

Value

Type

News

Receive news related to RECURSION PHARMACEUTICALS, INC.

Track Activities on RXRX

Account